9 Meters Biopharma, Inc. (NMTR) Stock Analysis

9 Meters Biopharma, Inc. (NMTR) Healthcare & Pipeline Overview

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for rare digestive diseases and gastrointestinal disorders. Their focus on unmet needs in conditions like celiac disease and short bowel syndrome positions them within the competitive biotechnology landscape, emphasizing innovative peptide and antibody-based treatments.

What Is the Investment Thesis for NMTR?

9 Meters Biopharma presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on rare digestive diseases addresses a significant unmet medical need, potentially leading to substantial market exclusivity and pricing power if its lead candidates are approved. The Phase 3 clinical trial of Larazotide for celiac disease represents a near-term catalyst, with positive results potentially driving significant stock appreciation. However, the company's limited financial resources and dependence on successful clinical trial outcomes pose substantial risks. Investors should closely monitor clinical trial data, regulatory milestones, and the company's ability to secure additional funding to assess the viability of this investment. The company's beta of 1.48 indicates higher volatility compared to the overall market.

Based on FMP financials and quantitative analysis

NMTR Key Highlights

Larazotide is in Phase 3 clinical trials for celiac disease, representing a potential near-term catalyst.

• Vurolenatide is in Phase 2 clinical trials for short bowel syndrome, targeting a rare and underserved market.
• The company has a pipeline of additional preclinical and clinical assets targeting various gastrointestinal disorders.
• 9 Meters Biopharma's focus on rare diseases may qualify for orphan drug designation, providing market exclusivity and regulatory advantages.
• The company's small size and limited resources present both opportunities for rapid growth and risks of financial instability.

Who Are NMTR's Competitors?

NMTR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NMTR's Key Strengths?

Focus on rare and underserved markets with high unmet medical needs.

• Proprietary technology platform for developing peptide and antibody-based therapies.
• Advanced clinical pipeline with lead candidates in Phase 3 and Phase 2 trials.
• Experienced management team with expertise in drug development and commercialization.

What Are NMTR's Weaknesses?

Limited financial resources and dependence on external funding.

• High risk of clinical trial failure and regulatory setbacks.
• Small size and lack of commercial infrastructure.
• Concentration of pipeline on a few key assets.

What Could Drive NMTR Stock Higher?

NMTR catalyst: Phase 3 clinical trial results for Larazotide in celiac disease (timeline dependent on trial progress).

• Potential regulatory submission for Larazotide pending successful Phase 3 trial results.
• Advancement of Vurolenatide through Phase 2 clinical trials for short bowel syndrome.
• Potential strategic collaborations or partnerships to expand the pipeline.
• Potential for orphan drug designation for lead product candidates.

What Are the Key Risks for NMTR?

Financial-distress signal — its Altman Z-Score of -49.88 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failure or regulatory setbacks for Larazotide and Vurolenatide.
• Inability to secure additional funding to support ongoing clinical trials and operations.
• Competition from larger pharmaceutical companies with greater resources.
• Dependence on a limited number of key assets in the pipeline.
• Economic downturn and reduced healthcare spending impacting market access and reimbursement.

What Are the Growth Opportunities for NMTR?

• Successful completion of the Phase 3 clinical trial for Larazotide in celiac disease could unlock a significant market opportunity. Celiac disease affects an estimated 1% of the population worldwide, and there are currently limited treatment options available. Positive trial results could lead to regulatory approval and commercialization, generating substantial revenue for 9 Meters Biopharma. The timeline for potential approval is estimated to be within the next 1-2 years, pending successful trial outcomes and regulatory review.
• The development of Vurolenatide for short bowel syndrome (SBS) represents another key growth driver. SBS is a rare and debilitating condition with a limited number of approved therapies. Vurolenatide's long-acting GLP-1 analog mechanism could offer improved efficacy and convenience compared to existing treatments. The market for SBS therapies is estimated to be worth several hundred million dollars annually, providing a significant revenue opportunity for 9 Meters Biopharma upon successful development and commercialization.
• Expansion of the pipeline through strategic collaborations and acquisitions could broaden 9 Meters Biopharma's therapeutic focus and reduce its reliance on Larazotide and Vurolenatide. Partnering with other biotech companies or academic institutions could provide access to new technologies and drug candidates, accelerating the company's growth trajectory. The timeline for potential collaborations is ongoing, as the company actively seeks opportunities to expand its pipeline.
• Securing orphan drug designation for its lead product candidates could provide significant market exclusivity and regulatory advantages. Orphan drug designation is granted to therapies targeting rare diseases, providing incentives such as tax credits, market exclusivity, and expedited regulatory review. This could enhance the commercial viability of Larazotide and Vurolenatide, making them more attractive to potential partners and investors.
• The development of NM-136, a humanized monoclonal antibody for targeted obesity disorders, presents a long-term growth opportunity. The obesity market is large and growing, driven by increasing prevalence and limited treatment options. NM-136's novel mechanism of action could offer a differentiated approach to weight management, potentially capturing a significant share of the market. However, the development timeline for NM-136 is longer-term, with several years of preclinical and clinical development required before potential commercialization.

What Are NMTR's Competitive Advantages?

• Patents protecting its drug candidates and formulations.
• Orphan drug designation for rare disease treatments, providing market exclusivity.
• Clinical trial data demonstrating efficacy and safety, creating a barrier to entry for competitors.
• Proprietary technology and know-how in the development of peptide and antibody-based therapies.

What Does NMTR Do?

9 Meters Biopharma, Inc., established to address the unmet medical needs in rare and debilitating digestive diseases, operates as a clinical-stage biopharmaceutical company. The company's foundation is rooted in the development of innovative therapies targeting gastrointestinal conditions that significantly impact patients' quality of life. Their lead product candidate, Larazotide, an 8-amino acid peptide, is currently in Phase 3 clinical trials for the treatment of celiac disease, a condition affecting millions worldwide. Additionally, Larazotide is also in Phase IIa clinical trial for the treatment of multi-system inflammatory syndrome. Another key asset is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 (GLP-1) analog, which is in Phase 2 clinical trial for the treatment of short bowel syndrome (SBS), a rare and complex condition characterized by the inability to absorb sufficient nutrients from food. Beyond these advanced programs, 9 Meters Biopharma is also developing NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. Headquartered in Raleigh, North Carolina, 9 Meters Biopharma is committed to advancing its pipeline and bringing meaningful therapeutic options to patients with limited treatment alternatives. The company's strategy involves a combination of internal research and development, as well as strategic collaborations to expand its portfolio and accelerate the development of its product candidates.

What Products and Services Does NMTR Offer?

• Develops Larazotide for the treatment of celiac disease.
• Develops Vurolenatide for the treatment of short bowel syndrome.
• Focuses on treatments for rare digestive diseases and gastrointestinal conditions.
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Seeks regulatory approval for its products from agencies like the FDA.
• Develops NM-102, a small molecule peptide.
• Develops NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease.
• Develops NM-136, a humanized monoclonal antibody for targeted obesity disorders.

How Does NMTR Make Money?

• Develops and patents novel therapeutic candidates.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approval to commercialize products.
• Potentially partners with larger pharmaceutical companies for commercialization and distribution.

What Industry Does NMTR Operate In?

The biotechnology industry is characterized by high levels of innovation, intense competition, and significant regulatory hurdles. Companies like 9 Meters Biopharma operate in a landscape dominated by larger pharmaceutical firms and specialized biotech companies focusing on specific therapeutic areas. The market for rare disease treatments is growing, driven by increased awareness, improved diagnostics, and regulatory incentives. However, the high cost of drug development and the uncertainty of clinical trial outcomes make this a high-risk, high-reward sector. Competitors like BiomX Inc. (BLCM), Caladrius Biosciences, Inc. (CWBR), and Cytosorbents Corporation (CYTO) operate in related fields, highlighting the diverse approaches to addressing unmet medical needs.

Who Are NMTR's Key Customers?

• Patients suffering from rare digestive diseases like celiac disease and short bowel syndrome.
• Healthcare providers who prescribe and administer the company's therapies.
• Pharmaceutical companies that may partner with 9 Meters Biopharma for commercialization.
• Payers, including insurance companies and government healthcare programs, that reimburse for the company's therapies.

How 9 Meters Biopharma, Inc. Is Valued

9 Meters Biopharma, Inc. carries a market capitalization of $1.04M, placing it in the micro-cap category.

Company Profile

9 Meters Biopharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Raleigh, US. The company is led by CEO Bethany Sensenig. NMTR has traded publicly since 2016.

9 Meters Biopharma, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -49.88 places it in the distress zone, a signal of elevated financial risk.

The most recent 12 insider filings for 9 Meters Biopharma, Inc. break down as 1 sales and 11 purchases. On net that is roughly 767K shares acquired (about $141K) — insiders putting money in tends to read as conviction.

NMTR Financials

NMTR Latest News

No recent news available for NMTR.

9 Meters Biopharma, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources